Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study by Rozemeijer, K. (Kirsten) et al.
the bmj | BMJ 2017;356:j504 | doi: 10.1136/bmj.j504
RESEARCH
1
open access
1Department of Public Health, 
Erasmus MC, University Medical 
Center, 3000 CA Rotterdam, 
Netherlands
2PALGA, the nationwide network 
and registry of histo- and 
cytopathology in the 
Netherlands, Houten, 
Netherlands
3Clinical Research Centre and 
Department of Pathology, 
Copenhagen University 
Hospital, Hvidovre, Denmark
4Department of Pathology, 
Erasmus MC, University Medical 
Center, Rotterdam, Netherlands
Correspondence to: S K Naber 
s.naber@erasmusmc.nl
Cite this as: BMJ 2017;356:j504
http://dx.doi.org/10.1136/bmj.j504
Accepted: 08 January 2017
Cervical cancer incidence after normal cytological sample in 
routine screening using SurePath, ThinPrep, and conventional 
cytology: population based study
Kirsten Rozemeijer,1 Steffie K Naber,1 Corine Penning,1 Lucy I H Overbeek,2 Caspar W N Looman,1 
Inge M C M de Kok,1 Suzette M Matthijsse,1 Matejka Rebolj,3 Folkert J van Kemenade,4 
Marjolein van Ballegooijen1 
ABSTRACT
ObjeCtive
To compare the cumulative incidence of cervical cancer 
diagnosed within 72 months after a normal screening 
sample between conventional cytology and liquid 
based cytology tests SurePath and ThinPrep.
Design
Retrospective population based cohort study.
setting
Nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA), January 
2000 to March 2013.
POPulatiOn
Women with 5 924 474 normal screening samples 
(23 833 123 person years).
exPOsure
Use of SurePath or ThinPrep versus conventional 
cytology as screening test.
Main OutCOMe Measure
72 month cumulative incidence of invasive cervical 
cancer after a normal screening sample for each 
screening test. Cox regression analyses assessed the 
hazard ratios, adjusted for calendar time, age, 
screening history, and socioeconomic status and 
including laboratories as random effects.
results
The 72 month cumulative cancer incidence was 58.5 
(95% confidence interval 54.6 to 62.7) per 100 000 
normal conventional cytology samples, compared with 
66.8 (56.7 to 78.7) for ThinPrep and 44.6 (37.8 to 52.6) 
for SurePath. Compared with conventional cytology, 
the hazard of invasive cancer was 19% lower (hazard 
ratio 0.81, 95% confidence interval 0.66 to 0.99) for 
SurePath, mainly caused by a 27% lower hazard (0.73, 
0.57 to 0.93) of a clinically detected cancer. For 
ThinPrep, the hazard was on average 15% higher 
(hazard ratio 1.15, 0.95 to 1.38), mainly caused by a 
56% higher hazard of a screen detected cancer (1.56, 
1.17 to 2.08).
COnClusiOns
These findings should provoke reconsideration of the 
assumed similarity in sensitivity to detect progressive 
cervical intraepithelial neoplasia between different 
types of liquid based cytology and conventional 
cytology.
Introduction
The use of conventional cytology as the primary test 
method has been replaced by the use of liquid based 
cytology in many countries with organised cervical can-
cer screening programmes, such as the UK, the Nether-
lands, and Denmark.1 2  The main advantages of using 
liquid based cytology instead of primary conventional 
cytology are facilitation of reflex testing (that is, the 
residual material can be tested for the presence of the 
human papillomavirus in case of borderline/mildly dys-
karyotic smears)3 4  and reduction in the number of 
slides of unsatisfactory quality.5-9 The sensitivity of liq-
uid based cytology for detecting cervical intraepithelial 
neoplasia (CIN) II+ lesions is believed to be similar to 
that of conventional cytology.10 11  However, the litera-
ture has been dominated by many studies comparing 
CIN detection between ThinPrep and conventional 
cytology,12-17  whereas only two studies have compared 
CIN detection between SurePath and conventional 
cytology.7 18 Therefore, we compared CIN II+ detection 
rates between these three types of cytology tests in our 
previous study, including more than six million smears 
taken within the Dutch cervical cancer screening pro-
gramme.19 Whereas the use of SurePath led to an 8% 
increase in detection of CIN II+ compared with conven-
tional cytology, the use of ThinPrep did not affect CIN 
II+ detection rates. These results were compatible with 
the results of other studies.12-16  20
Detecting more CIN as a result of an abnormal screen-
ing test is expected to deplete the pool of lesions that 
would have progressed to cancer. However, in the 
absence of screening (and associated treatment) only a 
fraction of screen detected CIN would progress to 
WhAT IS AlReAdy knoWn on ThIS TopIC
The general consensus is that sensitivity for cervical intraepithelial neoplasia (CIN) 
II+ is similar between liquid based cytology and conventional cytology
However, recent studies have shown that sensitivity for detecting CIN II+ lesions 
depends on the type of liquid based cytology test used (SurePath or ThinPrep)
Whether differences exist in the sensitivity for progressive CIN II+ lesions between 
SurePath, ThinPrep, and conventional cytology is unknown
WhAT ThIS STudy AddS
Using SurePath rather than conventional cytology or ThinPrep as the primary test 
method was associated with lower cervical cancer rates diagnosed after a normal 
screening sample
This strongly suggests that the sensitivity of SurePath to detect progressive CIN 
lesions is higher
Using ThinPrep rather than conventional cytology as the primary test method 
seemed to be associated with higher cervical cancer rates diagnosed after a normal 
screening sample, although differences were non-significant
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 cervical cancer (that is, the progressive CIN lesions), so 
detecting more CIN lesions is not always equivalent to 
preventing more cervical cancers. To assess whether the 
ability to detect progressive CIN lesions differs between 
the types of screening tests, the probability of a diagno-
sis of invasive cervical cancer in the period after a nor-
mal test result (the progressive CIN that screening has 
missed) has to be compared. As the incidence of inva-
sive cervical cancer after a normal test result is low (six 
year cumulative incidence rate 48 (95% confidence 
interval 43 to 54) per 100 000 normal smears),21 such a 
comparison can be made only by using an observa-
tional population based study in which a large number 
of samples can be evaluated.
In the Netherlands, organised cervical cancer screen-
ing has existed since the 1980s, and women aged 30 to 
60 years have been invited every five years since 1996. 
Until 2016, the screening strategy consisted of primary 
cytology screening with cytology triage testing, the lat-
ter either alone or in combination with human papillo-
mavirus testing. All cervix uteri cytological and 
histological tests taken inside and outside the Dutch 
screening programme are registered in the nationwide 
network and registry of histo- and cytopathology in the 
Netherlands (PALGA).22 By using these data, we 
assessed the cumulative incidence of invasive cervical 
cancer detected within 72 months after a normal screen-
ing test result (diagnosed in the next screening round or 
outside the organised Dutch screening programme). If 
this incidence varies among the three tests (SurePath, 
ThinPrep, and conventional cytology), the sensitivity 
for progressive CIN lesions probably differs between 
them. In addition, we stratified for the reason for cervi-
cal examination that led to the detection of cervical 
cancer (screen detected when programme smear 
detected or clinically detected in all other cases, which 
includes opportunistic screening as well as direct biop-
sies).
Methods
Information on all cytological and histological exam-
inations of the cervix uteri taken in the Netherlands 
between January 2000 and March 2013 were available 
and retrieved from the national PALGA database. Multi-
ple quality checks ensured the reliability of the retrieved 
data.23 24 We identified women through their birth date 
and the first eight letters of their (maiden) family name. 
This identification code enables linkage of multiple 
tests belonging to the same woman, allowing us to fol-
low individual screening histories.
We identified and selected episodes starting with a 
normal primary screening sample taken within the 
Dutch screening programme between January 2000 and 
March 2012. We identified screening samples through 
the reason for taking the sample being participation in 
the programme, which is routinely registered in PALGA. 
We also selected women with a primary sample of inad-
equate quality followed by a normal sample within the 
same episode. We defined an episode as starting with a 
primary test followed by one or more secondary tests in 
case the result was abnormal (at least borderline or 
mild dyskaryosis) or of inadequate quality. Unless the 
follow-up of a primary test had already been completed 
according to the guidelines (for example, by two con-
secutive normal samples after a screening result with 
borderline dyskaryosis), we considered tests taken 
within four years after a primary test to be secondary 
tests.25 We labelled all other tests as primary tests.
We stratified normal primary screening samples by 
the type of cytology test used (SurePath, ThinPrep, or 
conventional cytology). As PALGA does not register this 
routinely, regional coordinating pathologists obtained 
conversion dates (fixed to the first date of the yearly 
quarter) from the individual laboratories located in 
their region. In the Netherlands, it is standard practice 
for laboratories to supply general practitioners with 
cytology kits and thereby determine the type of cytology 
test that is used. We linked these conversion dates to the 
laboratory involved and the examination date as a 
proxy for which type of primary cytology test was used.
Follow-up ended at the date of the primary test of the 
next episode, which resulted in a cervical cancer diagno-
sis (a case) or not, on 31 March 2013 (the end of the data-
base), or on completion of the 72 month period, whichever 
came first. We censored the follow-up at 72 months 
because it covers the invitation for the next screening 
round, which takes place 60 months after a normal 
screening sample. By definition, after a normal primary 
screening test, all new tests give rise to a new episode 
regardless of the reason for taking the test and the type of 
test. We identified histologically confirmed cases of cervi-
cal cancer by selecting all PALGA records that included 
pathology codes describing invasive cancers originating 
in the cervix uteri. These codes were manually checked to 
avoid over-counting of both non-invasive lesions and pri-
mary cancers originating elsewhere.
As women in the Netherlands are invited for screen-
ing in the year they turn 30, 35, 40, 45, 50, 55, and 60, we 
categorised age as 29-33, 34-38, 39-43, 44-48, 49-53, 
54-58, and 59-63 years at the time of the normal primary 
cytological sample. We also defined calendar year at the 
time of the normal cytological sample. We defined 
socioeconomic status, categorised as low, middle, or 
high, by the status score. This is an ecological variable 
based on the household characteristics of the four digit 
postcode area where the woman was living at the time 
of the primary test.26 Status scores per four digit postal 
code came from the Netherlands Institute for Social 
Research and were based on mean income, percentage 
of households with a low income, percentage of house-
holds with (on average) a low education, and unem-
ployment rate in 2010. Low socioeconomic status 
corresponded to a status score lower than −1 (that is, 
average status score minus 1 standard deviation), inter-
mediate socioeconomic status to a score of between −1 
and 1, and high socioeconomic status to a score higher 
than 1 (that is, average status score plus 1 standard devi-
ation). We categorised screening history as no history of 
cytological smears (inside or outside the screening pro-
gramme) before the normal screening sample, one cyto-
logical smear that was taken less than seven years 
before the normal screening sample, one cytological 
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smear that was taken more than seven years before the 
normal screening sample, at least two cytological 
smears with the last being taken less than seven years 
before the normal screening sample, and at least two 
cytological smears with the last being taken more than 
seven years before the normal screening sample.
statistical analyses
Laboratories implemented liquid based cytology testing 
at different points in time. Therefore, we expected fol-
low-up and calendar time to differ between the three 
types of cytology tests. As demographic characteristics 
of screened women (age, screening history, and socio-
economic status) probably differed between laborato-
ries, we expected them to differ between the types of 
cytology tests as well. As age, socioeconomic status, 
screening history, and calendar time were all associated 
with CIN and/or cervical cancer detection rates,27-30 they 
were all potential confounding factors. We used a Pear-
son’s χ2 test to test whether their distributions differed 
between the types of cytological tests. We considered a 
P value of less than 0.05 to be statistically significant. 
We imputed missing values with 10 imputation sets.
Cumulative incidence and hazard ratio
For each type of cytology test, we did a Kaplan-Meier 
analysis to calculate the cumulative incidence of inva-
sive cervical cancer per 100 000 normal cytological 
screening samples. We took differences in follow-up 
time into account and estimated the 95% confidence 
intervals by non-parametric Kaplan-Meier product-limit 
estimator for log(hazard).21 31 We used the R package 
“coxme” to do multilevel Cox regression analyses to 
compare the hazard of cervical cancer between the 
types of cytology tests, taking differences in follow-up 
time into account and adjusting for the confounding 
factors calendar time, socioeconomic status, age, and 
screening history. We included the determinant labora-
tory as a random effect in the model to take account of 
clustering of the data at the laboratory level. In addi-
tion, we stratified for the reason for the cervical exam-
ination that led to the cervical cancer diagnosis (that is, 
screen detected when detected by a programmed smear 
or clinically detected in all other cases, including 
opportunistic screening as well as direct biopsies). We 
tested time dependencies of the hazard ratios statisti-
cally by splitting the total follow-up time into two peri-
ods with a roughly equal number of cases. Subsequently, 
we assessed hazard ratios for each time period. If the 
sum of the deviance of both sub-models was signifi-
cantly lower than the deviance of the original model, 
we considered the hazard ratio to be time dependent as 
it differed significantly between the time periods.
Sensitivity analyses
In the first sensitivity analysis, we restricted our Cox 
regression analysis to women with at least one previous 
smear. In the subsequent sensitivity analysis, we 
selected only women who attended the next screening 
round (within six years after a normal screening test 
result) in order to examine the effect that possible 
 differences in the attendance rates at the next screening 
might have had on the comparisons between the cytol-
ogy tests. We repeated the latter analysis in the third 
sensitivity analysis with the addition of an extra con-
founding factor, the type of cytology test used in the 
subsequent screening round. We did this to correct for 
the potential differences in the sensitivity of the subse-
quent screening test.
Difference in CIN detection rates per 100 000 
screening samples and 72 month cumulative cervical 
cancer incidence after 100 000 normal screening 
samples
We assessed the difference in CIN detection rates per 
100 000 SurePath and 100 000 ThinPrep samples (com-
pared with the CIN detection rates per 100 000 conven-
tional cytology samples) and compared it with the 
difference in the 72 month cumulative cervical cancer 
incidence after 100 000 SurePath and ThinPrep normal 
screening samples. Information on the calculation of 
the difference in detection rates per 100 000 primary 
screening samples can be found in the supplementary 
material. We calculated the 72 month cumulative cancer 
incidence rates for SurePath and ThinPrep by multiply-
ing the distribution of the 72 month cumulative cancer 
incidence rate for conventional cytology with the distri-
bution of the adjusted hazard ratios for SurePath and 
ThinPrep versus conventional cytology, as obtained by 
Cox regression.
Patient involvement
No patients or women eligible for screening were 
involved in the design and conduct of the study, nor 
were they involved in defining the research question or 
outcome measures. We have no intentions to dissemi-
nate our results to patients or women eligible for 
screening.
Results
Within the follow-up period, 1042 invasive cervical can-
cers were diagnosed after 3 028 865 normal conven-
tional cytology samples, 231 cancers were diagnosed 
after 1 303 817 normal SurePath samples, and 328 can-
cers were diagnosed after 1 591 792 normal ThinPrep 
samples (table 1). This corresponds to 7.6, 4.8, and 6.3 
cervical cancer diagnoses per 100 000 person years, 
respectively.
Crude cumulative incidence
Compared with conventional cytology, the 12, 24, 36, 48, 
60, and 72 month cumulative incidences of invasive cer-
vical cancer were significantly lower for SurePath (fig 1). 
When we compared SurePath with ThinPrep, all but the 
24 month cumulative incidences were significantly 
lower for SurePath. No significant differences were 
apparent between ThinPrep and conventional cytology. 
The 72 month cumulative incidence was 44.6 (95% con-
fidence interval 37.8 to 52.6) after 100 000 normal Sure-
Path samples, 58.5 (54.6 to 62.7) after 100 000 normal 
conventional cytology samples, and 66.8 (56.7 to 78.7) 
after 100 000 normal ThinPrep samples.
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Distribution of potential confounding factors
The distribution of calendar time differed signifi-
cantly between the methods of cytology testing 
(P<0.001). In 2000 94% of the included normal 
screening samples consisted of conventional cytol-
ogy, whereas by 2012 this percentage had dropped to 
2% (fig 2 ). We also observed a large significant differ-
ence for the distributions of follow-up time. For 
instance, almost 80% of the normal conventional 
cytology samples had a follow-up time of at least 48 
months, whereas for SurePath and ThinPrep this was 
the case for slightly more than 50% and 35% of the 
normal samples, respectively. Small but significant 
differences were also present in the distributions 
of  socioeconomic status, screening history, and 
age  (table 1). Missing values were imputed for 
 socioeconomic status (1.4% of the primary normal 
samples had a missing value).
Cox regression analyses of invasive cervical cancers
When we compared SurePath with conventional cytol-
ogy, the hazard of an invasive cancer was significantly 
lower (hazard ratio 0.81, 95% confidence interval 0.66 
to 0.99) (table 2). This decreased hazard was mainly 
caused by a decreased hazard of a clinically detected 
cancer (that is, not detected through programme 
screening) (hazard ratio 0.73, 0.57 to 0.93); the hazard of 
a screen detected cancer was similar to that of conven-
tional cytology (0.95, 0.72 to 1.27).
When we compared ThinPrep with conventional 
cytology, the hazard of an invasive cancer was on aver-
age non-significantly higher (hazard ratio 1.15, 0.95 to 
1.38). This effect seemed to differ over time (P=0.063), 
with a hazard ratio of 0.95 (0.75 to 1.22) in the first 44 
months after the normal screening smear and of 1.40 
(1.07 to 1.83) thereafter. This overall increased hazard 
was caused by an increased hazard of a screen detected 
table 1 | Characteristics of normal screening samples and their follow-up for conventional cytology, surePath, and thinPrep. values are numbers 
(percentages) unless stated otherwise
 Characteristics Conventional surePath thinPrep P value
Normal screening samples 3 028 865 1 303 817 1 591 792
Person years at risk 13 796 018 4 835 917 5 201 188
Normal screening sample followed by subsequent screening* 1 931 397 (63.8) 445 726 (34.2) 370 519 (23.3) <0.001
Median (interquartile range) normal screening samples per woman 1 (1-2) 1 (1-1) 1 (1-1) <0.001
Invasive cervical cancers diagnosed after normal screening sample 1042 231 328 <0.001
Screen detected† 414 84 103 <0.001
Clinically detected‡ 628 147 225 <0.001
Follow-up time:
<0.001
 0-12 months 208 668 (6.9) 73 905 (5.7) 95 563 (6.0)
 12-24 months 105 945 (3.5) 191 027 (14.7) 321 784 (20.2)
 24-36 months 129 165 (4.3) 187 410 (14.4) 311 295 (19.6)
 36-48 months 203 768 (6.7) 189 063 (14.5) 284 262 (17.9)
 48-60 months 920 825 (30.4) 334 677 (25.7) 339 590 (21.3)
 60-72 months, 1 460 494 (48.2) 327 735 (25.1) 239 298 (15.0)
Age, years:
<0.001
 29-33 411 873 (13.6) 167 015 (12.8) 193 998 (12.2)
 34-38 503 889 (16.6) 187 179 (14.4) 217 213 (13.6)
 39-43 516 728 (17.1) 218 559 (16.8) 267 194 (16.8)
 44-48 482 822 (15.9) 218 476 (16.8) 267 585 (16.8)
 49-53 434 620 (14.3) 192 594 (14.8) 240 801 (15.1)
 54-58 381 312 (12.6) 173 572 (13.3) 219 277 (13.8)
 59-63 297 621 (9.8) 146 422 (11.2) 185 724 (11.7)
Screening history:
<0.001
 No history§ 396 174 (13.1) 167 880 (12.9) 194 251 (12.2)
 1 smear ≤7 years¶ 446 673 (14.7) 156 727 (12.0) 183 294 (11.5)
 1 smear >7 years** 35 164 (1.2) 15 388 (1.2) 20 003 (1.3)
 ≥2 smears ≤7 years†† 2 095 417 (69.2) 941 575 (72.2) 1 164 713 (73.2)
 ≥2 smears >7 years‡‡ 55 437 (1.8) 22 247 (1.7) 29 531 (1.9)
Socioeconomic status:
<0.001
 Low 248 097 (8.2) 153 494 (11.8) 108 492 (6.8)
 Middle 2 501 696 (82.6) 1 038 602 (79.7) 1 337 521 (84.0)
 High 232 658 (7.7) 87 193 (6.7) 132 863 (8.3)
 Unknown 46 414 (1.5) 24 528 (1.9) 12 916 (0.8)
Clinically detected cancer=not detected through programme screening.
*These differences are mainly caused by differences in follow-up time (see also fig 2). Differences in length of follow-up were accounted for in all analyses. Sensitivity analyses were restricted to 
women with subsequent attendance at screening programme.
†Include all cancers detected in first screening round following normal screening sample of ThinPrep, SurePath, or conventional cytology. 
‡Include all cancers detected outside screening programme following normal screening sample of ThinPrep, SurePath, or conventional cytology.
§No history of cytological smears (inside or outside screening programme) before normal screening sample.
¶History of one cytological smear taken <7 years before normal screening sample.
**History of one cytological smear taken >7 years before normal screening sample.
††History of ≥2 cytological smears, last taken <7 years before normal screening sample.
‡‡History of ≥2 cytological smears, last taken >7 years before normal screening sample.
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cancer (hazard ratio 1.56, 1.17 to 2.08), whereas the haz-
ard of a clinically detected cancer was unaffected (0.96, 
0.76 to 1.20).
When we compared SurePath with ThinPrep, the haz-
ard of an invasive cancer was significantly lower (haz-
ard ratio 0.71, 0.58 to 0.87). This decreased hazard was 
caused by both a decreased hazard of a clinically 
detected cancer (hazard ratio 0.76, 0.59 to 0.97) and a 
decreased hazard of a screen detected cancer (0.61, 0.46 
to 0.81).
sensitivity analyses
When selecting only women with at least one smear 
before the normal screening sample, we found that the 
hazard ratios were consistent with the main analyses 
(not restricted to women with a screening history), 
although the effect of ThinPrep versus conventional 
cytology seemed to be somewhat less pronounced 
(table 2). When selecting only women who attended 
programme screening within 72 months after a normal 
screening test result, we found that the hazard of a 
screen detected cancer increased slightly for both Sure-
Path and ThinPrep versus conventional cytology. The 
hazard of a screen detected cancer for SurePath versus 
ThinPrep remained similar to the main analyses.
Of those women with conventional cytology at base-
line followed by a subsequent screening round, 36% 
were re-screened with conventional cytology, 20% with 
SurePath, and 37% with ThinPrep. For the remaining 
7%, the type of cytology test at re-screening was 
unknown. Of those with SurePath at baseline, 52% were 
re-screened with SurePath, 21% with ThinPrep, 4% with 
conventional cytology, and 23% with an unknown type 
of test. Of those with ThinPrep at baseline, 55% were 
re-screened with ThinPrep, 6% with SurePath, 3% with 
conventional cytology, and 36% with an unknown type 
of test. The addition of the test method in the subse-
quent screening round as a confounding factor resulted 
in hazard ratios similar to the ones in the second sensi-
tivity analysis (without this extra confounder).
Difference in Cin detection rates and 72 month 
cumulative invasive cervical cancer incidence
The difference in the detection of CIN II+ for SurePath 
and conventional cytology, as observed previously,19 
was consistent with the observed difference in cumula-
tive incidence of cervical cancer after a normal screen-
ing sample. The use of SurePath as primary test method 
resulted in 94.4 (95% confidence interval 68.9 to 120.6) 
extra CIN diagnoses per 100 000 screening samples, 
whereas the 72 month cumulative incidence of cervical 
cancer decreased by 11.9 (−15.6 to −4.2) (table 3). The 
use of ThinPrep versus conventional cytology showed 
quite different results. Whereas the number of CIN diag-
noses was similar to that with conventional cytology, 
the 72 month cumulative incidence of cervical cancer 
increased by 8.5 (−0.7 to 18.8) after 100 000 normal 
screening test results.
discussion
The risk of invasive cervical cancer was 19% lower after 
a normal SurePath sample than after a normal conven-
tional cytological sample, which was mainly caused by 
a 27% lower risk of a clinically detected cancer (that is, 
not detected through programme screening). The use of 
SurePath resulted in 12 fewer cervical cancers per 
100 000 normal screening samples, whereas the num-
ber of detected CIN lesions increased by 94. The risk of 
invasive cervical cancer seemed to be 15% higher for 
ThinPrep in comparison to conventional cytology, but 
the magnitude of the difference seemed to differ over 
time. Within the first 44 months after the normal screen-
ing sample, the risks were comparable; thereafter, the 
risk was 40% higher when using ThinPrep. Both the 
increased risk and the difference over time were mainly 
due to a 56% higher risk for a screen detected cancer. 
The use of ThinPrep resulted in eight additional cervical 
cancers per 100 000 normal screening samples, 
whereas the number of detected CIN lesions was 
slightly but not statistically significantly lower.
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strengths and limitations of study
This study is the first to compare rates of invasive cervi-
cal cancer detected after a normal screening sample 
between two different types of liquid based cytology 
tests and conventional cytology, a widely accepted 
proxy for examining differences in the sensitivity to 
detect progressive CIN lesions. In addition, we exam-
ined the drawbacks of implementation of liquid based 
cytology by comparing indicators of over-diagnosis.
Our study has some limitations. Firstly, we were not 
able to correct for the use of automated reading, 
although the possible influence would be small given 
that automated reading has been introduced in rela-
tively few Dutch laboratories. Moreover, multiple stud-
ies have shown that CIN II+ detection was unaffected or 
slightly decreased by adding automated assisted read-
ing to ThinPrep or SurePath.32-34  Secondly, as we did not 
have a unique identification code (the identification 
code was based on the first eight letters of the (maiden) 
family name and birth date), tests belonging to different 
women may have been allocated to a single woman 
(so-called fusions). However, we think it unlikely that 
these fusions would be correlated with the type of cytol-
ogy test used. Thirdly, we did not have individual data 
on which type of primary test was used. Therefore, we 
used the date of the primary cytological smear and lab-
oratory’s conversion date fixed to the first date of the 
quarter to deduce which type of cytology test was used. 
This means that normal screening samples taken 
during this quarter may have been misclassified to 
some extent, leading to a slight underestimation of the 
effects. Fourthly, we were not able to censor follow-up 
for death and migration. However, as both mortality 
and migration rates are relatively low at screening 
ages,35 36 we do not expect that this has biased our 
results. Fifthly, restricting our analyses to squamous 
cell carcinomas, adenocarcinomas, and/or micro-inva-
sive and macro-invasive carcinomas was not possible, 
table 3 | Cin detection rates per 100 000 screening samples and 72 month cumulative cervical cancer incidence after 100 000 normal screening samples 
for conventional cytology, and difference in those measures for surePath and thinPrep compared with conventional cytology
Conventional 
cytology
surePath v 
conventional 
cytology
thinPrep v 
conventional cytology
no of Cin diagnoses per 100 000 screening samples
CIN I 216.1 30.1 (18.1 to 42.8) −3.5 (−14.3 to 7.9)
CIN II 220.0 31.2 (19.0 to 44.1) 9.4 (−2.1 to 21.5)
CIN III 495.0 30.3 (12.0 to 49.3) −12.2 (−29.6 to 5.9)
Total CIN 931.0 94.4 (68.9 to 120.6) −6.8 (−30.6 to 17.6)
no of cervical cancer diagnoses after 100 000 normal screening samples*
Total cancers 58.5 (54.6 to 62.7) −11.9 (−15.6 to −4.2) +8.5 (−0.7 to 18.8)
Numbers were corrected for confounding factors. 95% confidence intervals are given in parentheses.
CIN=cervical intraepithelial neoplasia.
*Differences in distribution of follow-up were taken into account, and laboratories were included as random effects in model.
table 2 | Hazard ratio of cervical cancer after normal surePath or thinPrep screening sample compared with after normal conventional screening sample 
and compared with each other, overall and stratified by reason for cervical examination that led to cancer diagnosis
Main analyses sensitivity analyses: adjusted Hr (95% Ci)
unadjusted Hr 
(95% Ci)
adjusted Hr  
(95% Ci)
(1) restricted to 
women with ≥1 
previous smear
(2) restricted to 
women attending 
programme screening
(3) as for (2) + test method 
in subsequent screening 
round as confounding factor
all cancers
SurePath v CC 0.74 (0.64 to 0.85) 0.81 (0.66 to 0.99)* 0.80 (0.64 to 0.99) NA NA
ThinPrep v CC 1.07 (0.95 to 1.22) 1.15 (0.95 to 1.38)† 1.09 (0.89 to 1.34) NA NA
SurePath v ThinPrep 0.69 (0.58 to 0.81) 0.71 (0.58 to 0.87)‡ 0.73 (0.58 to 0.91) NA NA
Clinically detected cancers
SurePath v CC 0.70 (0.59 to 0.84) 0.73 (0.57 to 0.93)§ 0.71 (0.54 to 0.92) NA NA
ThinPrep v CC 1.03 (0.88 to 1.20) 0.96 (0.76 to 1.20)¶ 0.91 (0.71 to 1.16) NA NA
SurePath v ThinPrep 0.68 (0.55 to 0.84) 0.76 (0.59 to 0.97)** 0.78 (0.60 to 1.02) NA NA
screen detected cancers
SurePath v CC 0.80 (0.64 to 1.02) 0.95 (0.72 to 1.27)†† 0.94 (0.68 to 1.29) 1.01 (0.72 to 1.41) 1.02 (0.71 to 1.47)
ThinPrep v CC 1.16 (0.93 to 1.44) 1.56 (1.17 to 2.08)†† 1.58 (1.15 to 2.16) 1.65 (1.18 to 2.28) 1.62 (1.15 to 2.29)
SurePath v ThinPrep 0.70 (0.52 to 0.93) 0.61 (0.46 to 0.81)†† 0.59 (0.43 to 0.81) 0.61 (0.44 to 0.86) 0.63 (0.43 to 0.90)
Differences in follow-up were taken into account; hazard ratios are shown unadjusted and adjusted for laboratory (included as random effect), age, socioeconomic status, screening history, and 
calendar time.
CC=conventional cytology; HR=hazard ratio; NA=not applicable.
*HR was not time dependent; P=0.559.
†HR seemed to be time dependent, although not significantly; P=0.063.
‡HR was not time dependent; P=0.667.
§HR was not time dependent; P=0.658.
¶HR was not time dependent; P=0.306.
**HR was not time dependent; P=0.954.
††Time dependencies not calculated for screen detected cancer, as they occur only approximately 60 months after baseline.
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as this information in PALGA is not accurate and many 
values are missing. Finally, we did not correct for possi-
ble learning curve effects, as the aim of our study was to 
examine the effect of using SurePath and ThinPrep in 
routine practice, which also includes a possible learn-
ing effect.
effect of confounding factors and sensitivity 
analyses
As laboratory and calendar time were clearly correlated 
with the moment of implementation of liquid based 
cytology, their confounding effects were much more 
pronounced than those of age, screening history, and 
socioeconomic status. Although significantly different, 
their distribution differences were very small and, 
therefore, confounding effects were negligible. It is pos-
sible that we did not take into account the effect of other 
(unknown) potential confounders. The fact that we 
found no large differences in age, screening history, and 
socioeconomic status is reassuring, however.
We found that the effect of ThinPrep compared with 
conventional cytology seemed to be somewhat less pro-
nounced in women with a screening history compared 
with our main analysis (also including women without 
a screening history). This suggests that the risk of a cer-
vical cancer after a normal ThinPrep screening sample 
is perhaps increased more in women without versus 
with a screening history.
Restricting the analysis to women who attended the 
next screening round slightly increased the risk of a 
screen detected cancer for both SurePath and ThinPrep, 
although the difference between these two types of liq-
uid based cytology test remained similar. This may have 
resulted in a slight underestimation of the hazard ratios 
between SurePath and conventional cytology and 
between ThinPrep and conventional cytology.
In an ideal situation, the type of cytology test used 
would differ between the groups only at baseline to 
ensure that results are not biased by differences in sen-
sitivity to detect a cervical cancer in the episode follow-
ing the normal screening sample. Our finding that the 
addition of the second type of test (in the subsequent 
episode) as confounder did not change our results was 
reassuring.
explanation of main results
In our previous study, using the same data as in this 
study, we showed that the detection of CIN II+ was 
increased by using SurePath compared with conven-
tional cytology, whereas it was unaffected by using 
ThinPrep.19 As the use of SurePath resulted in decreased 
rates of cervical cancer after a normal screening sam-
ple, this indicates that at least part of the extra detected 
CIN lesions were progressive. As the use of ThinPrep 
seemed to result in increased cancer rates, this suggests 
that fewer of the detected CIN lesions were progressive.
In addition, we showed that the use of SurePath was 
associated with lower rates of cervical cancer after a 
normal screening sample compared with the use of 
ThinPrep, indicating that the sensitivity to detect 
 progressive CIN lesions is higher for SurePath. These 
suggested differences in sensitivity are most likely 
caused by differences between the techniques of the liq-
uid based cytology tests, such as the extent of fixation, 
the technique of taking a representative sample from 
the vial, and the retention of the brush (the collecting 
device) in the fluid.37 38  Studies have shown that retain-
ing the brush, as is done when using SurePath, is asso-
ciated with an increased cell yield compared with 
rinsing and discarding the brush, as is done when using 
ThinPrep.39  40
extrapolation of results
The cumulative incidence of cancer after a normal sam-
ple seemed to be higher for ThinPrep than for conven-
tional cytology mainly because the risk of a screen 
detected cancer after a normal sample was higher. In 
general, screen detected cancers are found at a lower 
stage than clinically diagnosed ones, so their survival 
rate is probably better.41 Therefore, the suggested nega-
tive effect of using ThinPrep is probably less pro-
nounced for cervical cancer mortality than it is for 
incidence. The opposite is true for the positive effect of 
SurePath, as we found that SurePath was primarily pro-
tective for clinically detected cancers. As no data on 
mortality were available, we were not able to estimate 
the effects of implementation of liquid based cytology 
on cervical cancer mortality. Although our results may 
not seem very relevant for the future of the Dutch cervi-
cal cancer screening programme, as primary cytology 
screening has recently been replaced by primary 
human papillomavirus screening, they will certainly be 
relevant to other countries with organised primary 
cytology screening programmes that have switched to 
using SurePath and/or ThinPrep or will switch in the 
near future.
Over-diagnosis
An important drawback of cervical cancer screening is 
over-diagnosis and over-treatment of CIN lesions (that 
is, of lesions that would never have progressed to clini-
cal cervical cancer in the absence of screening). The 
possible increase in such over-diagnosis and over-treat-
ment related to more sensitive screening should be 
taken into account when considering new screening 
options. With SurePath, the prevention of 12 extra cervi-
cal cancers within the first six years after screening was 
accompanied by the detection of 94 extra CIN lesions at 
that screening round. Most of these CIN lesions would 
never have become invasive cancer and could therefore 
be classified as over-diagnosis. Assuming that only CIN 
II+ are treated, replacing conventional cytology with 
SurePath would have implied that roughly five more 
CIN treatments are performed to prevent one additional 
cervical cancer diagnosis. However, in a subsequent 
screening round for the same cohort, increased detec-
tion rates tend to wane, and so do over-diagnosis and 
over-treatment. This effect was also observed in ran-
domised controlled trials in which cytology screening 
was replaced by highly sensitive human papillomavirus 
based screening in the intervention arm. The detection 
of high grade CIN was increased at the prevalence 
doi: 10.1136/bmj.j504 | BMJ 2017;356:j504 | the bmj
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round but decreased at the subsequent incidence 
round, accompanied by a reduced risk of interval can-
cers.42 43 Therefore, in our study, the number of addi-
tional CIN treatments per additionally prevented cancer 
is, if anything, overestimated.
Comparison with literature
Whether one cytology test is preferred over another 
should depend not only on the sensitivity to detect pro-
gressive CIN lesions and rates of over-diagnosis but also 
on factors such as the possibility to test for the presence 
of human papillomavirus in the residual material and 
the percentage of unsatisfactory smears. Fontaine et al 
have shown that unsatisfactory rates are significantly 
lower when using SurePath instead of ThinPrep.44 
Although this was not shown in our previous study,19 
we then found similar results (an odds ratio of 0.74, 0.72 
to 0.75) when comparing unsatisfactory rates between 
SurePath and ThinPrep.
Conclusions
The six year cumulative incidence of cervical cancer 
after a normal screening sample was significantly lower 
for SurePath than for conventional cytology and Thin-
Prep, strongly suggesting that the sensitivity of Sure-
Path to detect progressive CIN lesions is higher. The use 
of ThinPrep compared with the use of conventional 
cytology seemed to be associated with a higher cumula-
tive cancer incidence, suggesting that the sensitivity to 
detect progressive CIN lesions is lower, although results 
were non-significant. Our findings should provoke 
reconsideration of the assumed similarity in the sensi-
tivity for progressive CIN between the different types of 
liquid based cytology tests and conventional cytology.
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